Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Plasma cell 1Myeloid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Graft vs Host Disease 1Bronchiolitis Obliterans Syndrome 1

Interventions

pembrolizumab 184Carboplatin 130Paclitaxel 123Gemcitabine 122Docetaxel 96Cyclophosphamide 89Nivolumab 88Cisplatin 87Rituximab 71Dexamethasone 68Pemetrexed 64Bevacizumab 64Capecitabine 60atezolizumab 54fludarabine 49Azacitidine 49Fluorouracil 48130-nm albumin-bound paclitaxel 43venetoclax 41Trastuzumab 41Irinotecan 41Cetuximab 40Leucovorin 36Ipilimumab 36Erlotinib Hydrochloride 34Fulvestrant 32Cytarabine 32avelumab 31Oxaliplatin 31Albumin-Bound Paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × milatuzumab × Clear all
NCT01585688 2021-10-08

Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL

Gilead Sciences

Phase 1/2 Terminated
13 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01663766 2021-08-19

Phase I Study of Milatuzumab for Graft Versus Host Disease

Gilead Sciences

Phase 1 Terminated
12 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡